MGNX News and Press, MacroGenics Inc. From 07/18/22

Shares of micro-cap company MacroGenics ( NASDAQ: MGNX ) fell ~19% to $3.41 in Monday trading, as a rating downgrade by SMBC Nikko Securities weighed on the stock. SMBC Nikko lowered its rating on MGNX to neutral from outperform, citing the halt of the company's mid-stag...

Gainers: Qudian ( QD ) +48% . Marathon Digital ( MARA ) +32% . SQL Technologies ( SKYX ) +27% . SOS ( SOS ) +25% . Hut 8 Mining ( HUT ) +24% . North European Oil Royalty Trust ( NRT ) +24% . Advent Technologies ( ...

BMO Capital Markets has downgraded MacroGenics ( NASDAQ: MGNX ) to Market Perform from Outperform after the oncology-focused biotech announced the termination of a Phase 2 trial for a cancer regimen targeted at the squamous cell carcinoma of the head and neck. The price target l...

After reporting on July 8 that it was terminating a phase 2 clinical trial for its treatment aimed at metastatic squamous cell carcinoma of the head and neck (SCCHN), MacroGenics ' (NASDAQ: MGNX) saw its stock drop by more than 10.8% on Monday as of 10:36 a.m. ET. The company sa...

Oncology-focused biotech MacroGenics ( NASDAQ: MGNX ) has decided to close its Phase 2 study for an investigational treatment regimen after a review of safety data revealed seven fatalities. The study named CP-MGA271-06 was designed to evaluate monoclonal antibody enoblitu...

Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor  ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings  ( SWVL ) ...

ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022, the Company cl...

Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...

Shares of MacroGenics (NASDAQ: MGNX) were skyrocketing 27.8% higher as of 12:47 p.m. ET on Tuesday. The sharp gain appears to be related to insider buying of the stock. A filing to the U.S. Securities and Exchange Commission on June 17 revealed that MacroGenics CFO James Karrels rec...

Gainers: Convey Health Solutions Holdings (CNVY) +139%. Valneva (VALN) +86%. Green Giant (GGE) +78%. CEA Industries (CEAD) +76%. Clovis Oncology (CLVS) +71%. Tabula Rasa HealthCare (TRHC) +34%. Revlon (REV) +34%. Innate Pharma (IPHA) +33%. Sorrento Therapeutics (SRNE) +28%. MacroGenics (MGNX)...